相关上市企业：溢多利（300381）、蔚蓝生物（603739）、星湖科技（600866）、唐人神（002567）、 新希望（000876）、神农集团（605296）、海大集团（002311）、大北农（002385）、粤海饲料 （001313）、金新农（002548）等。 相关企业：北京昕大洋科技发展有限公司、科明（岳阳）工业科技有限公司、济南天天香有限公司、济 南百斯杰生物工程有限公司、夏盛(北京)生物科技开发有限公司、江苏奕农生物股份有限公司、山东隆 科特酶制剂有限公司、潍坊瑞辰生物科技有限公司等。 关键词：植酸酶行业产业链、植酸酶行业产量、植酸酶行业竞争格局、植酸酶行业发展趋势 一、植酸酶行业相关概述 内容概要：植酸酶作为一种重要的生物酶，在饲料、食品等多个领域有广泛应用。其中饲料领域的需求 增加是推动植酸酶市场增长主要因素，特别是在2020年我国全面禁止饲料中添加抗生素后，植酸酶逐渐 成为抗生素的理想替代品。近年来，随着中国生物技术的快速发展和市场需求的不断扩大，国内植酸酶 的年产量已显著提升。数据显示，2015年中国植酸酶行业产量达到4.32万吨，到了2024年行业产量增长 至12.06万吨。预计未来 ...

【全新修订】：2025年11月 全球食品饮料用纤维素酶行业发展动态与前景需求规模调查报告2026年版 【出版机构】：鸿晟信合研究院 【内容部分有删减·详细可参鸿晟信合研究院出版完整信息！】 【免费售后 服务一年，具体内容及订购流程欢迎咨询客服人员 】 报告目录 1 统计范围及所属行业 1.1 产品定义 1.2 所属行业 1.3 产品分类，按产品类型 2.5.2 2024年食品饮料用纤维素酶主要企业在中国市场排名（按收入） 2.5.3 近三年中国市场主要企业食品饮料用纤维素酶销售收入（2022-2025） 2.6 全球主要厂商食品饮料用纤维素酶总部及产地分布 2.7 全球主要厂商成立时间及食品饮料用纤维素酶商业化日期 2.8 全球主要厂商食品饮料用纤维素酶产品类型及应用 1.3.1 按产品类型细分，全球食品饮料用纤维素酶市场规模2020 VS 2024 VS 2031 1.4 产品分类，按应用 1.4.1 按应用细分，全球食品饮料用纤维素酶市场规模2020 VS 2024 VS 2031 1.3.2 EG 1.3.3 CBH 1.3.4 BG 1.4.2 食品工业 1.4.3 饮料行业 1.5 行业发展现状分析 ...

Core Insights - The article discusses the first batch of bio-manufacturing landmark products announced by Hubei Province's Economic and Information Technology Department on October 9, highlighting significant advancements in the bio-manufacturing sector [2]. Group 1: Landmark Products - The first batch of landmark bio-manufacturing products includes: - Dongyang Sunshine: Thiocyanate Erythromycin - Tianji Bioenergy: Ultra-clean biodiesel - Bafeng Pharmaceutical: Amino acid raw materials - Xinhua Yang: Feed enzyme preparations - Guangji Pharmaceutical: High-quality riboflavin - China National Pharmaceutical Group: Inactivated vaccine for Porcine Circovirus Type 2 - Aibotai Bio: Research antibodies - Huisheng Biotechnology: Tylosin tartrate - Hite Bio-pharmaceutical: Injectable Epinephrine - Fuxing Biotechnology: Arachidonic acid (ARA) powder [2][3]. Group 2: Product Categories - The products are categorized into different types: - Scale Replacement Type: Thiocyanate Erythromycin, Ultra-clean biodiesel, Research antibodies, Tylosin tartrate - Key Improvement Type: Amino acid raw materials, Feed enzyme preparations, High-quality riboflavin, Arachidonic acid powder - Major Innovation Type: Inactivated vaccine for Porcine Circovirus Type 2, Injectable Epinephrine [3].

Core Insights - The event held on October 15 in Hubei aimed to strengthen collaboration between universities, research institutions, and enterprises in the biomanufacturing sector, establishing a platform for innovation and competitiveness in the industry [1][2] - The event showcased three national-level and ten provincial-level biomanufacturing landmark products, highlighting the advanced technology and economic benefits of these innovations [2] - Hubei University is positioning itself as a leader in synthetic biology in Central China, focusing on breakthroughs in gene editing, enzyme development, and industrial strain design [3][4] Group 1: Event Overview - The event was organized by the Hubei Provincial Department of Economy and Information Technology and included participation from various government officials and industry leaders [1] - Keynote speeches were delivered by prominent scientists and representatives from major companies, emphasizing the importance of biomanufacturing [1] Group 2: Collaboration and Agreements - Hubei University signed multiple cooperation agreements with local governments and enterprises, focusing on technology research and development in areas such as strain modification and enzyme engineering [2] - The event included a signing ceremony for collaborative agreements, indicating strong industry-academia partnerships [2] Group 3: Industry Significance - Biomanufacturing is recognized as a "green engine" for new productive forces and a core area of global technological competition, reshaping industries like pharmaceuticals and food [3] - Hubei's biomanufacturing sector benefits from a multi-dimensional support system, with Hubei University playing a crucial role in advancing life sciences [3][4] Group 4: Achievements and Impact - Hubei University has made significant advancements in technology and innovation, leading multiple national research projects and achieving high rankings in academic performance [4] - The university's contributions have generated substantial economic benefits for the local region, with technology service revenues exceeding 250 million yuan annually [4]

Core Insights - The 2025 China Small and Medium Cities High-Quality Development Index was released, highlighting the achievements of Yishui County in various national rankings [1] - Yishui County has improved its overall strength ranking, moving up 2 places to 85th, and has received three national honors in green development, investment potential, and new urbanization quality [1] Group 1: Industrial Development - Yishui County emphasizes industrial economy as a cornerstone for high-quality development, focusing on biomanufacturing and fine chemicals as key industries [1] - The county has established a "command + chain leader + special team" mechanism to enhance industrial growth, with a total industrial output value of 59.07 billion yuan, reflecting a year-on-year growth of 5.8% [2] Group 2: Urban-Rural Integration - Towns are seen as a bridge for urban-rural integration, with successful examples like Xujiahukou Town leveraging local resources for cultural and economic development [2] - Xujiahukou Town ranked 495th among the national top 1,000 towns, while Yangzhuang Town made its debut on the list at 983rd, showcasing the effectiveness of rural revitalization efforts [2] Group 3: Infrastructure and Public Services - Infrastructure improvements are underway, including transportation and public service upgrades, enhancing the quality of life for residents [3] - Initiatives such as old community renovations and public service enhancements are contributing to a better living environment and community well-being [3] Group 4: Social Development - The county's social development is marked by strong governance and community engagement, with events like the 2025 Shandong (Yishui) Food Expo attracting nearly 400 quality enterprises [3] - Cultural initiatives and community programs are fostering a vibrant social atmosphere, promoting reading and cultural activities [3] Group 5: Future Prospects - Yishui County's comprehensive development strategy positions it favorably in the competitive landscape of county-level governance, contributing to the revitalization of the Yimeng revolutionary area [4] - The county aims to continue enhancing its industrial base, urban-rural integration, and social welfare to achieve sustainable growth [4]

Core Insights - The event "Biomanufacturing Leading the Future" was successfully held in Hefei as part of the 2025 World Manufacturing Conference, attracting over 230 participants from various sectors [1][3] - The focus was on the biomanufacturing industry, discussing key common links and development hotspots, and aiming to create a comprehensive biomanufacturing ecosystem [3][4] Industry Development - Anhui Province has established a comprehensive biomanufacturing industry system covering six sectors: biopharmaceuticals, bio-food, bio-energy, biomaterials, biochemistry, and enzyme preparations [3] - The province has developed three billion-level industry clusters in biopharmaceuticals, bio-food, and bio-energy, with leading companies like Huaheng Bio and Fengyuan Group [3][4] - A 3 billion yuan biomanufacturing industry fund has been established through cooperation between central and local governments [3] Strategic Initiatives - Hefei is integrating biomanufacturing into its new industrial cluster system, forming a dedicated task force and implementing supportive policies [4] - The establishment of the Synthetic Biology Innovation Research Institute and the Hefei (Changfeng) Synthetic Biomanufacturing Industrial Park aims to create a nationally influential biomanufacturing hub [4] Collaborative Efforts - Key projects and funds were signed during the event, including the Synthetic Biology Multiscale Incubation Center and AI-driven biomanufacturing platforms [4] - The establishment of the Anhui Biomanufacturing Industry Alliance will facilitate the gathering of innovative resources and promote the commercialization of research outcomes [7] Future Outlook - Anhui plans to optimize its industrial layout and enhance collaboration among government, industry, academia, research, finance, and services to foster a "four-chain integration" industrial ecosystem [8]

Core Insights - The event "Biomanufacturing Leading Future Industrial Pattern" held in Changfeng, Hefei, is part of the 2025 World Manufacturing Conference, focusing on biomanufacturing as a key industry [1][3] - The Hefei Biomanufacturing Provincial Future Industry Pilot Zone is the only pilot zone in Anhui Province dedicated to life sciences [1][3] Group 1: Event Overview - The event emphasized the importance of biomanufacturing, discussing key common links and hot subfields, and aimed to promote industrial integration and cluster development [3] - The Hefei Biomanufacturing Provincial Future Industry Pilot Zone was officially approved in October 2024, with plans for the Hefei Synthetic Biomanufacturing Industrial Park [3] Group 2: Industry Development - The pilot zone has made significant progress in its first year, with major projects like the AI-driven biomanufacturing R&D base and microbial agent technology application base set to be completed soon [3] - The pilot zone currently hosts two listed biomanufacturing companies, with one more planning to go public next year, and five key enterprises are expected to achieve a combined output value of 4 billion yuan in 2024 [3][4] Group 3: Regional Focus - Anhui Province has established a comprehensive biomanufacturing industry system covering six sectors, with biopharmaceuticals, bio-foods, and bio-energy clusters each exceeding 10 billion yuan in scale [4] - Changfeng County aims to reach a biomanufacturing output value of 15 billion yuan by 2027 and over 30 billion yuan by 2030, with plans to establish four provincial-level innovation platforms and cultivate ten leading enterprises [5][7]

Group 1 - The core viewpoint of the article is the announcement of a new patent for a strain of Trichoderma reesei, which is expected to enhance the production of acidic cellulase enzymes in industrial applications [1] - The patented strain, E619, was preserved on September 25, 2024, at the China General Microbiological Culture Collection Center, indicating a formal recognition and potential for commercial use [1] - The development of this strain is anticipated to meet the growing demand for acidic cellulase enzymes in China, providing significant supply support for the industry [1]

Market Overview - The report provides a comprehensive analysis of the global and Chinese non-starch polysaccharide enzyme market, including market size forecasts and strategic insights for the period 2025-2031 [1][3] - Non-starch polysaccharide enzymes are categorized into soluble and insoluble types, with distinct sales growth trends projected from 2020 to 2031 [4][6] Sales Growth Trends - The sales revenue growth trends for different product types of non-starch polysaccharide enzymes are analyzed for the years 2020, 2024, and 2031, indicating a significant increase in market demand [4][9] - The report highlights the sales growth trends across various applications, including food and beverage, chemicals, and other sectors, with specific revenue forecasts [4][8] Industry Background and Trends - The current status and historical development of the non-starch polysaccharide enzyme industry are discussed, along with future development trends [4][9] - The report outlines the supply and demand dynamics of the global non-starch polysaccharide enzyme market, including production capacity, output, and utilization rates from 2020 to 2031 [5][6] Regional Analysis - A detailed analysis of the production and sales trends of non-starch polysaccharide enzymes across major global regions, including North America, Europe, China, Japan, Southeast Asia, and India, is provided [5][6] - The report includes market share data for different regions, highlighting the competitive landscape and growth opportunities [5][6] Major Manufacturers - The report identifies key global manufacturers of non-starch polysaccharide enzymes, detailing their production capacities, sales volumes, and revenue rankings for 2024 [5][6] - Specific insights into the market positions and product offerings of major players such as Du Pont, Novozymes, and BASF are included, along with their recent developments [6][7] Product and Application Analysis - The report categorizes non-starch polysaccharide enzymes by product type and application, providing sales volume and revenue forecasts for 2020-2031 [8][9] - Price trends for different product types and applications are analyzed, indicating market pricing dynamics over the forecast period [8][9] Industry Opportunities - The report discusses the opportunities and driving factors for the non-starch polysaccharide enzyme industry, emphasizing the potential for growth in various applications [9][10] - An analysis of the industry value chain, including upstream raw material supply and downstream customer segments, is provided [9][10]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 increased to approximately $394,000 compared to $335,000 for the same period last year, driven by an increase in grants revenue of approximately $210,000 from the Gates Foundation and CEPI [15] - Research and development expenses for Q1 2025 decreased to $495,000 from $523,000 year-over-year, reflecting a decrease in ongoing internal research projects [16] - General and administrative expenses decreased by 10.8% to $1,596,000 compared to $1,789,000 for the same period last year [17] - Net loss for Q1 2025 was $2,028,000 or $0.07 per share, compared to $2,010,000 or $0.07 per share for the same period last year [18] Business Line Data and Key Metrics Changes - The focus is on commercializing high-value recombinant enzymes and proteins, particularly in life sciences, nutrition, and industrial applications [4][5] - The top commercialization priority lies in the cell culture media space, valued at over $6.1 billion globally, growing at a 13% compound annual growth rate [6] - Significant progress is being made in the development of recombinant human serum albumin, with expectations for launch in Q3 2025 [7] Market Data and Key Metrics Changes - The animal-free dairy products market was valued at approximately $26.5 billion in 2023, with increasing partner interest in non-animal dairy proteins [9] - The nucleic acid tools market is projected to exceed $4 billion globally by 2028, with ongoing development of recombinant DNase-one and RNase-free enzymes [8] Company Strategy and Development Direction - The core growth strategy is centered on high-value life sciences, bioactives, ingredients, and industrial markets, aiming for sustainable growth in non-pharmaceutical sectors [5] - The company is focusing on product development rather than platform development, prioritizing commercialization-ready products [35][36] - Strategic partnerships are maintained in vaccine therapeutic developments, with collaborations with CEPI and the Gates Foundation [4][12] Management's Comments on Operating Environment and Future Outlook - Management emphasizes the importance of transitioning from a development stage to a product-driven revenue-generating enterprise [62] - The company is well-positioned to meet global demand for scalable and affordable animal-free precision engineered proteins and enzymes [63] - There is a commitment to strengthening the balance sheet to support near-term revenue growth and strategic objectives [18] Other Important Information - The company has cash and investment-grade securities of $7.4 million as of March 31, 2025, down from $9.4 million as of December 31, 2024 [18] - The company is participating in various funded programs, including a $4.5 million grant from CEPI and a $3 million program funded by the Gates Foundation [11][12] Q&A Session Summary Question: Can you explain the royalty arrangement with Fermbox? - The profit split is significant for both companies, and revenue sharing will begin immediately as sales start rolling in [22][23] Question: What is the progress on the albumin arrangement? - No advanced orders have been placed yet; sampling is expected to begin in Q2 2025 [24] Question: Will there be opportunities for Fermbox to bid on other contracts? - There are ongoing evaluations for additional contracts in both government and private sectors [27] Question: When will the company start spending less on research and more on revenue-generating areas? - The company is currently reprioritizing resources towards non-pharmaceutical sectors for revenue generation [34][36] Question: What product in the non-dairy applications portfolio has the best margins? - Lactoferrin has the highest margin potential, while alpha-lactalbumin has the largest market potential [40][41] Question: Is there any quantifiable tariff problem for the company? - Currently, there are no significant tariff issues, and there may be potential opportunities with onshoring [50] Question: Will the albumin and dairy enzymes be produced in the U.S.? - Yes, both products are being produced domestically, which mitigates tariff concerns [54][55]